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Control mechanisms of normal differentiation are disrupted in cancer cells but can be restored by treatment with site- 
selective CAMP analogs. The cellular events associated with such changes entail compartmental redistribution of the 
CAMP-dependent protein kinase type II regulatory subunit, RI&+ The results of this study indicate that the molecular 
mechanisms of action involve changes in specific DNA-binding activity of putative transcription factors. Gel retardation 
analyses revealed that nuclear extracts from cells of various human cancer cell lines [colon cancer (LS-174T), gastric can- 
cer (TMK-l), and leukemia (K-562)] and rodent pheochromocytoma (PC12) show a concentration-dependent i crease 
in binding activity to a synthetic DNA that contained the CAMP-responsive lement S-TGACGTCA-3’ after treatment 
with 8-Cl-cAMP. Such an increase in CAMP-responsive lement binding activity was not observed in the 8-Cl-cAMP- 
unresponsive MKN-1 gastric cancer cells. These findings indicate that the antitumor activity of site-selective CAMP ana- 
logs may reside in the induction of transcription factors that restore normal gene regulation in cancer cells. 
Gel retardation; Transcription factor; cyclic AMP responsiveness 
1. INTRODUCTION 
In mammalian cells, gene expression is altered in 
response to stimulation by hormones. Stimuli 
whose action is mediated through adenylate cyclase 
and CAMP-dependent protein kinase influence the 
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transcriptional efficiency of several genes through 
the binding of specific factors to distinct &acting 
DNA sequences located in the 5 ‘-noncoding (pro- 
moter) region [ 11. Recently, a region containing the 
CAMP-responsive element (CRE) has been shown 
to bind specific nuclear proteins from various 
tissues [2-41. In recent reports [S-7] we 
demonstrated that human and rodent cancer cells 
show growth inhibition and changes in mor- 
phologic appearance and biochemical properties 
after treatment with site-selective CAMP analogs. 
These effects were not mimicked by previously 
studied analogs such as dibutyryl-CAMP. Of the 
two known CAMP-binding sites in protein kinase 
regulatory subunits, the C-8 halogen analogs 
preferentially bind to site 1 (site B) of type II pro: 
tein kinase [8,9]. The apparent underlying cellular 
mechanism of 8-Cl-CAMP, the most potent growth 
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inhibitor, is to promote translocation of type II 
CAMP-dependent protein kinase regulatory sub- 
unit (RIIp) (see [lo] for nomenclature) from the 
cytoplasm to the nucleus [l 11. 
Site-selective CAMP analogs also have induced 
differentiation in several leukemic cell lines [12]. 
The molecular events underlying these changes 
have not been elucidated but are suggested to in- 
volve specific factors that play a regulatory role in 
transcription [13]. In this study, we examined 
whether or not the regulatory role of site-selective 
CAMP analogs on the growth and differentiation 
of cancer cells would involve modulation of gene 
transcription. To assess such transcriptional 
modulation, we examined the change in the DNA 
(CRE)-binding activity of nuclear extracts 
prepared from cancer cells after treatment with 
8-Cl-CAMP. 
2. MATERIALS AND METHODS 
2.1. Materials 
The cell lines used in this study were cancer cells, such as 
LS-174T (human colon carcinoma) 15,111, K-562 (chronic 
myelogenous human leukemia) [12,13], PC12 (rodent pheo- 
chromocytoma), and TMK-1 and MKN-1 (8-Cl-cAMP- 
responsive and -unresponsive human gastric cancers, respective- 
ly) [14], that were demonstrated previously to be responsive to 
treatment with site-selective CAMP analogs. The cells were 
grown under standard conditions and treated for l-3 days with 
8Cl-CAMP at indicated concentrations as previously described 
[5,12]. ~-C&CAMP was kindly provided by R.K. Robins 
(Nucleic Acid Research Institute, Costa Mesa, CA). 
The CRE-containing oligonucleotide used in this study con- 
tained the TGAG sequence as the first 5 ’ to 3 ’ downstream bases 
and GTCA as the next sequence. A 3-fold repeat of this se- 
quence with a complementary second strand and a 5’-di- 
nucleotide overhang was synthesized (MIM no. 001, Synthecell 
Corporation, Gaithersburg, MD). The double-stranded trioc- 
tamer of CRE was labeled with 32P at the 5 ‘-end using T4 kinase 
[15]. Cold competition assays were performed using (i) a 200-bp 
oligonucleotide containing CRE sequences (SS-200) prepared 
from the promoter region of somatostatin-CAT fusion gene 
[A-71 CAT; kindly provided by M. Montminy (Salk Institute, 
La Jolla, CA)] and (ii) a 323-bp segment of the early promoter 
region of SV40 DNA (SV40-323) containing no CRE sequences 
Ml. 
2.2. Preparation of nuclear extracts 
Nuclear extracts were prepared by previously published 
methods with a minor modification [11,17]. Briefly, a homo- 
genate was prepared in 0.35 M sucrose solution containing 
0.05 M Tris, pH 7.5, 5 mM EDTA, 2 mM mercaptoethanol, 
1 mM phenylmethylsulfonyl fluoride, and 1 mM benzamide. A 
Dounce homogenizer was used to disrupt cells while preserving 
nuclear and organellar integrity. The crude nuclear pellet (ob- 
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tained by centrifuging at 5000 x g for 10 min) was washed in 
phosphate-buffered saline, extracted with 0.4 M NaCl, and sub- 
jected to centrifugation at 25 000 x g for 60 min. The superna- 
tant fraction from this centrifugation was used for gel mobility 
assays. When proteins were purified from this extract, am- 
monium sulfate was added to 45% saturation, the precipitate 
was collected in the cold by centrifugation at 16ooO x g for 
20 min, and the solubilized pellet was dialyzed and used for 
assays. Protein concentrations were determined by the method 
of Lowry et al. [18] with bovine serum albumin as standard. The 
nuclear extracts were stored in aliquots at - 80°C. 
2.3. Gel retardation assay 
The DNA-binding assay was performed by a method 
modified from that of Fried and Crothers [19]. Nuclear extracts 
at the indicated concentrations were incubated with 0.5-1.5 ng 
of labeled oligonucleotide for 30 min at 30°C. The poly dI. dC 
concentration (Sigma Chemical Co., St. Louis, MO) was 
titrated and found to be optimal for eliminating nonspecific 
mobility retardation in the concentration range of 1.5-5.0/g 
per assay. Other DNA preparations were added when indicated, 
and the reaction was terminated by the addition of 2.5 ~1 of 
bromophenol blue and xylene cyanole (0.1% each in 50% 
glycerol). The samples were then applied to a 4% acrylamide gel 
(30: 1 acryl/bis) and separated at 200 V for 1.5 h at room 
temperature. The gels were dried, and the gel mobility retarda- 
tion was visualized by autoradiography using X-OMAT film 
(Eastman Kodak, Rochester, NY). Densitometry was carried 
out using a Hoefer Scientific Instruments GS 300 scanning den- 
sitometer and analyzed using the Macintosh version of the 
GS-370 data system. 
3. RESULTS 
LS-174T human colon cancer cells grown in 
culture in the presence of 8-Cl-CAMP (10pM) 
demonstrated an increase in CRE DNA-binding ac- 
tivity in their nuclei (fig. 1) and cytoplasm (data not 
shown). At least 25 pg of nuclear proteins or 30 pg 
of cytoplasmic proteins were required to 
demonstrate this activity. At protein concentra- 
tions below these limits, no gel retardation activity 
was shown in either control or treated cell extracts. 
Formation of DNA-protein complexes with the 
32P-labeled CRE-containing oligonucleotide was 
also demonstrated in purified nuclear protein 
preparations from K-562 human leukemia and 
PC12 rat pheochromocytoma cell lines (fig.2A and 
B). The nuclear proteins from K-562 and PC12 cell 
lines treated with 8-Cl-CAMP showed a 
concentration-dependent increase in gel mobility 
retardation of the CRE trioctamer (lanes 2,4,6, and 
8) when compared with the DNA binding in the un- 
treated control nuclei (lanes 1,3,5, and 7). 
The DNA-binding activity in 8-Cl-cAMP- 
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Fig.1. Binding activity of CRE-oligonucleotide with nuclear ex- 
tracts from LS-174T colon cancer cells before and after treat- 
ment with &Cl-CAMP. Lanes: 1, DNA alone; 2 and 3, in- 
cubated with nuclear extracts from untreated control cells; 4 and 
5, nuclear extracts from cells treated for 72 h with 10 PM &Cl- 
CAMP. Crude nuclear extracts were used. The letter B on the 
right of this and the subsequent wo figures refers to bound 
DNA and the letter F to free DNA. 
responsive (TMK-1) and -unresponsive (MKN-1) 
gastric cancer cell lines [14] is shown in fig.3. B-Cl- 
CAMP treatment increased the DNA binding in 
IMK-1 nuclear extracts (fig.3A) but not in MKN-1 
(fig.3B). In MKN-1, there was a decrease in DNA 
binding after B-Cl-CAMP treatment. 
A 0.5 1 2 4 rg Protein 
d8-CI Cs-CI d8-CI C&% 01 OI+BSA 
12345676910 
Densitometric analysis indicated that there is 
some variability in DNA-binding activity depen- 
ding on the cell type relative to the protein concen- 
tration at which the binding saturation takes place. 
The quantification data of DNA binding with 
respect to protein concentrations are shown in 
fig.4. Saturation of DNA-binding activity in the 
nuclear proteins of LS174T colon cancer cells was 
not observed, even at protein concentrations as 
high as 8 pug protein per assay, and the binding in- 
creased throughout the range of concentrations 
tested; the binding was 2-fold greater in the cells 
treated with B-Cl-CAMP than in the untreated con- 
trol cells. Both treated and untreated PC12 cells 
reached their saturation in DNA binding at 3-4 pg 
nuclear proteins per assy, and the binding activity 
was 3-5-fold greater in the treated cells than in the 
untreated control cells (fig.4B). The nuclear pro- 
teins from TMK-1 cells treated with B-Cl-CAMP 
also showed progressively increasing binding ac- 
tivity at concentrations in the range of 3-16 /Ig pro- 
tein per assay (2-3-fold increase over the control 
values) (fig.4C). In B-Cl-CAMP-unresponsive 
MK&1 cells, this increase in DNA binding was not 
observed in the treated cell nuclei as compared with 
untreated control cells, even up to 16 ,ug protein per 
assay (fig.4D). 
Fig.5 shows competition of DNA-binding activi- 
ty in LS-174T cancer cells using unlabeled DNA 
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Fig.2. Comparison of 8-Cl-CAMP treatment on CRE DNA-binding activities in purified nuclear protein preparations from human 
K-562 leukemia and rodent Pcl2 pheochromocytoma cell lines. A, K-562 cells; B, PC12 cells. Nuclear proteins were purified as de- 
scribed in section 2. Lanes: 2,4,6, and 8, nuclear proteins from 8-Cl-CAMP-treated cells; 1,3,5, and 7, nuclear proteins from untreated 
cells; 9, DNA alone; 10, DNA plus 10 fig bovine serum albumin. K-562 cells were treated overnight with 1 ,uM 8-Cl-CAMP and PC12 
cells were treated for 72 h with 10 pM 8-Cl-CAMP. 
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Fig.3. DNA gel mobility retardation of 8-Cl-CAMP-responsive 
and -unresponsive gastric cell lines. A, TMK-1 (responsive) 
cells; B, MKN-1 (unresponsive) cells. Purified nuclear proteins 
were used. Lanes: 1,3,5, and 7, nuclear proteins from untreated 
cells; 2,4,6, and 8, nuclear proteins from cells treated with 
10 PM 8-Cl-CAMP for 72 h; 9 and 10, as in fig.2. 
with or without CRE sequences. There was little or 
no reduction in the DNA-binding activity by SV40 
promoter DNA, whereas somatostatin-CRE DNA 
caused a marked reduction (- 60%) in the DNA- 
binding activity in the 8-Cl-CAMP-treated cells. 
DNA binding of control nuclear proteins was 
decreased onbly 15-25% by somatostatin-CRE 
(data not shown). Interestingly, the extent of com- 
petition is considerably greater in the treated cells 
than in the controls, indicating that binding affini- 
ty with DNA may play a role or that more than one 
factor may be present. The Coomassie blue-stained 
protein patterns after SDS-PAGE of the treated 
and untreated cell nuclear extracts were identical 
(data not shown). 
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Fig.4. Protein concentration dependence of DNA complex for- 
mation of purified nuclear proteins from cells with and without 
treatment with 8-Cl-CAMP (10pM for 72 h). A, LS-174T; B, 
PC12; C, TMK-1; D, MKN-1. The values are integrated areas 
using a densitometric analysis of the DNA gel mobility retarda- 
tion and plotting the values (in arbitrary units, ordinate) against 
protein concentrations (abscissa). The values represent average 
f SD of five determinations. (o--o) Untreated control; 
(v) I-Cl-CAMP-treated. 
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Fig.5. Competition of gel retardation with CRE-containing 
DNA (SS-200) and DNA without CRE (SV40-323). Purified 
nuclear proteins (4 pg) from control and I-Cl-CAMP-treated 
(10pM for 72 h) LS-174T colon cancer cells were incubated 
with 32P-labeled CRE-oligonucleotide in the presence or absence 
of unlabeled SS-200 or SV40-323 (see section 2). Densitometric 
tracings of the DNA gel mobility retardation are shown by 
relative peak heights in arbitrary units (ordinate) against relative 
distance from origin (abscissa). 
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4. DISCUSSION 
Evidence presented in this work showed that a 
CAMP-dependent factor(s) capable of specific 
binding to a synthetic CRE oligonucleotide in- 
creases in cancer cells after treatment with a site- 
selective CAMP analog, 8-Cl-CAMP. The results 
are directly related to the responsiveness of cancer 
cells to treatment with the CAMP analog. The in- 
crease in DNA gel mobility shift was found in 
cancer cells, such as LS-174T colon carcinoma, 
TMK-1 gastric cancer, and K-562 leukemia, that 
have been shown [5,11-141 to be biologically 
responsive [growth inhibition, biochemical and 
morphological changes, induction of differentia- 
tion (leukemia), etc.] to 8-Cl-CAMP treatment. A 
gastric cancer cell line (MKN-I) which is biological- 
ly unresponsive to 8-Cl-CAMP, as indicated by 
continued growth during treatment [ 141, did not 
show an increase in such nuclear factor activity 
(fig.3). 
Responsiveness to normal control mechansism 
may be modified or lost in cancer cells [20-221. The 
link between transcriptional control and CAMP- 
directed pathways is the CRE [l]. Our demonstra- 
tion of an increase in DNA (CRE)-binding activity 
in only those cancer cells that are biologically 
responsive to the CAMP analog treatment suggests 
that the antineoplastic effect of site-selective 
CAMP analogs, which has been shown to be due to 
biological modulation rather than cell killing 
[5-7,l l-141, may reside in restoration of CRE- 
related transcriptional control in malignancy. 
The cellular events underlying the growth in- 
hibitory effect of site-selective CAMP analogs in- 
volve differential regulation of type I versus type II 
CAMP-dependent protein kinase isozymes [5-71. 
8-Cl-CAMP, in the inhibition of the growth of 
human colon cancer cells in culture, brought about 
an enhancement of the Rib nuclear translocation 
and transcriptional activation of R& receptor gene 
[l 11. Nuclear translocation of RI1 CAMP receptor 
protein, which has also been observed previously 
during cell development [23], tumor regression 
[24,25], and reverse transformation [26-281, there- 
fore suggests the possible role of this protein in 
gene regulation. It has been postulated [29] that the 
RI1 CAMP receptor proteins that bind CAMP [30] 
and DNA [31,32] and have amino acid homology 
with the Escherichia coli catabolite gene activator 
protein [33] could directly stimulate gene expres- 
sion. 
It has been reported [34] that a 43-kDa phospho- 
protein binds specifically to the region of the 
somatostatin gene known to contain CRE. This 
protein is suggested to be a substrate of both pro- 
tein kinase C and CAMP-dependent protein kinase, 
and its binding to DNA is not CAMP dependent. 
An increase of a transcriptional factor(s) upon 
CAMP stimulation has been shown in normal liver 
and hepatoma cell cultures using the CAMP- 
regulated gene encoding phosphoenolpyruvate car- 
boxykinase [35]. The relationship, if any, of these 
nuclear proteins to the protein(s) we detected is not 
known. 
Ultimate proof that the factor(s) we have 
detected are causally involved in the CAMP- 
mediated signal, however, will require the use of 
purified factor(s) and a suitable transcription 
system. Nevertheless, our findings may provide in- 
sight into the understanding of the fundamental 
mechanisms of gene control in cell proliferation 
and differentiation, and also importantly, they 
may iead to useful treatment protocols to identify 
responsive tumors whose growth can be controlled 
by the use of site-selective CAMP analogs, either 
alone or in combination with conventional chemo- 
therapeutic agents. 
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